Page 1

Third - Quarter 2021 Third Quarter Overall Net Sales $ 706.5M | 28.9 % Diluted Earnings Per Share : $ 2.31 | ↑ 112 % Adjusted Diluted Earnings Per Share : $ 2.06 | 79 % " We had robust growth in all three of our Proprietary Products market units , led by the sales of components in our High - Value Product ( HVP ) portfolio . This quarter's strong performance came from both our base business , especially in the Biologics market unit , and COVID - 19 related sales . Demand continues to grow for our premium offerings , such as NovaPure and FluroTec components , and , as a result , we are again increasing our planned capital expenditures , commencing next year , to expand HVP capacity at existing sites . " WST Q5 2021 Earnings Eric M. Green President and Chief Executive Officer West Pharmaceutical Services , Inc. OVERALL ORGANIC SALES GROWTH Proprietary Products Q3 2021 organic sales growth of 35.7 % , led by sales of high - value products , which grew double digits P BIOLOGICS GENERICS PHARMA CONTRACT MANUFACTURING West Q3 27.9 % DD DD DD LSD Abbreviations : LSD - low - single digit ; MSD - mid - single digit ; HSD - high - single digit ; DD - double digit Cautionary Statement Under the Private Securities Litigation Reform Act of 1995 This presentation and any accompanying management commentary contain " forward - looking statements " as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements include , but are not limited to , statements about product development and operational performance . Each of these statements is based on preliminary information , and actual results could differ from any preliminary estimates . We caution investors that the risk factors listed under " Cautionary Statement " in our press releases , as well as those set forth under the caption " Risk Factors " in our most recent Annual Report on Form 10 - K as filed with the Securities and Exchange Commission and as revised or supplemented by our quarterly reports on Form 10 - Q , could cause our actual results to differ materially from those estimated or predicted in the forward - looking statements . You should evaluate any statement in light of these important factors . Except as required by law or regulation , we undertake no obligation to publicly update any forward - looking statements , whether as a result of new information , future events , or otherwise . Non - U.S . GAAP Financial Measures Certain financial measures included in these presentation materials , or which may be referred to in management's discussion of the Company's results and outlook , have not been calculated in accordance with U.S. generally accepted accounting principles ( " U.S. GAAP " ) , and therefore are referred to as non U.S. GAAP financial measures . Non - U.S . GAAP financial measures should not be considered in isolation or as an alternative to such measures determined in accordance with U.S. GAAP . Please refer to " Reconciliation of Non - U.S . GAAP Financial Measures " at the end of these materials for more information . 1